http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020512323-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-02 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C311-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C211-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 |
| filingDate | 2018-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2020512323-A |
| titleOfInvention | Process for producing kinase inhibitor having sulfonamide structure |
| abstract | The present invention provides a kinase inhibitor having a sulfonamide structure, that is, N- (2 ′, 4′-difluoro-5- (5- (1-methyl-1H-pyrazol-4-yl) -1H-benzo [d] imidazole. -1-yl)-[1,1'-biphenyl] -3-yl) cyclopropanesulfonamide (1A) and an improved process for the preparation of its pharmaceutically acceptable salts. The compounds of formula (1A) are selective inhibitors of the FGFR / VEGFR kinase family and are useful in treating cancer. |
| priorityDate | 2017-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 104.